Rich McAvoy

Avid Bioservices, a leading contract development and manufacturing organization (CDMO) delivering process development and cGMP manufacturing services for biopharmaceutical products, has appointed Rich McAvoy as Chief Business Officer (CBO). 

The appointment further strengthens Avid’s executive leadership as the company continues to scale its operations and support the evolving needs of biopharmaceutical innovators.

McAvoy brings broad, business-focused leadership experience across strategic investment management, operational finance, accounting, legal, compliance, and enterprise risk management. Known for his disciplined and execution-driven approach, he is well positioned to help guide Avid’s long-term growth strategy while ensuring operational scalability and exceptional customer delivery. In his new role, McAvoy will focus on aligning commercial strategy with operational excellence to support sustained expansion across clinical and commercial manufacturing programs.

His appointment comes at a critical time for the biopharmaceutical industry, as sponsors increasingly reassess supply chain strategies amid geopolitical uncertainty, potential trade barriers, and a growing emphasis on strengthening U.S.-based manufacturing capabilities. Avid’s expanding infrastructure and integrated service offerings position the company as a trusted partner for organizations seeking reliable, domestic manufacturing solutions.

McAvoy’s leadership reinforces Avid Bioservices’ commitment to delivering high-quality cGMP manufacturing, responsive collaboration, and dependable execution. As the company continues to expand its capabilities and deepen partnerships across the biopharmaceutical ecosystem, Avid remains focused on helping customers advance critical programs efficiently from clinical development through commercial supply.